Company: CDT
Filing Date: 2025-06-09
Form Type: 8-K
Source: 0001641172-25-014322
Chunk: 0

Company: CDT Equity Inc.
Filing Date: 2025-06-09
Form: 8-K
Item: Item 1.01
Chunk 0
---
Item
1.01 Entry into a Material Definitive Agreement.

On
June 3, 2025, Conduit Pharmaceuticals Inc. (“ Conduit”) entered into a joint development agreement (the “ Joint Development
Agreement”) with Manoira Corporation (“ Manoira”) for a term of one year, which will be automatically renewed for successive
one-year terms unless advance termination notice is provided in accordance with the terms of the Joint Development Agreement. Manoira
is an entity controlled by Dr. Andrew Regan, of which he is sole director. Dr. Regan is a director and the Chief Executive Officer of
Conduit.

Pursuant
to the Joint Development Agreement, Conduit granted Manoira a non-exclusive, non-transferable, non-sublicensable, fully paid-up, royalty-free
license to the intellectual property rights related to the pharmaceutical compounds known individually and together as AZD1656 and AZD5658
(the “ Conduit Assets”). Manoira will evaluate the Conduit Assets’ applicability in animal health, explore veterinary
market opportunities, and provide data from the evaluations to inform Conduit’s human clinical programs. The license does not grant
Manoira the right to distribute, market, promote or sell the products or services that are related to or incorporate the Conduit Assets.

Effective
June 3, 2025, in exchange for the approximate $500,000 of consideration to be paid by Conduit under the Joint Development Agreement,
Conduit issued to Manoira 154,799 shares of its common stock, par value $0.0001 (the “ Common Stock”), (the “ Consideration
Shares”) valued at the closing price of the Common Stock immediately preceding execution of the Joint Development Agreement. The
Consideration Shares are being offered in reliance upon an exemption from the registration requirement of the Securities Act of 1933,
as amended (the “ Securities Act”), pursuant to Section 4(a)(2) thereof and/or Rule 506(b) of Regulation D promulgated thereunder,
and applicable state securities laws. The issuance of the Consideration Shares have not been registered under the Securities Act and
such securities may not be offered or sold in the United States absent registration or an exemption from registration under the Securities
Act and any applicable state securities laws. Manoira is acquiring the Consideration Shares for its own account with the present intention
of holding the Consideration Shares for investment purposes and not with a view to or for sale in